West China Hospital registers Phase 4 mazdutide trial in living liver donors
The 12-week randomized placebo-controlled study tests whether the GLP-1/glucagon dual agonist clears hepatic steatosis in donors disqualified by MASLD.
PR
By Priya Raman · Science Reporter
Sep 23 08:00 ETSource: ClinicalTrials.gov
The wire
- 01NCT07718126 began 1 September 2026: obese or overweight potential living liver donors with MASLD are randomized 1:1 to weekly subcutaneous mazdutide plus lifestyle counseling or placebo plus counseling.
- 02Primary endpoint is histological resolution of hepatic steatosis without worsening fibrosis at 12 weeks, aimed at expanding the living donor pool.
- 03Multicenter and recruiting; enrollment size, dose and completion date are not stated in the registration excerpt, and results are years away.
From the source
Read at clinicaltrials.govPre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME)
NCT07718126 · PHASE4 · RECRUITING · Sponsor: West China Hospital · Conditions: Metabolic Dysfunction-Associated Steatohepatitis, Hepatic Steatosis, Living Liver Donors.
Source URL https://clinicaltrials.gov/study/NCT07718126
